Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. 詳細を表示
SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat...
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025...
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 2, 2024...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome’s management will...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -0.373831775701 | 10.7 | 11.6 | 10.47 | 556114 | 10.97419414 | CS |
4 | -3.33 | -23.8027162259 | 13.99 | 14.1 | 10.11 | 846565 | 11.26448819 | CS |
12 | -1.62 | -13.1921824104 | 12.28 | 15.125 | 8.97 | 810027 | 11.52393452 | CS |
26 | -1.46 | -12.0462046205 | 12.12 | 16.81 | 8.97 | 720341 | 12.8220523 | CS |
52 | -0.69 | -6.07929515419 | 11.35 | 30.958 | 8.97 | 762666 | 15.44465275 | CS |
156 | -1.02 | -8.73287671233 | 11.68 | 30.958 | 2.09 | 315036 | 13.79577311 | CS |
260 | -5 | -31.9284802043 | 15.66 | 63.78 | 2.09 | 281834 | 15.72146231 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約